drugset
drugset / Trial / NCT05993975

Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine

NCT05993975 ↗

Phase 4 Completed 108 enrolled Sindh Institute of Urology and Transplantation
RandomizedParallel-groupDouble-blindSupportive care

Summary

Patients will be enrolled in one of the two groups using a computer-generated random number table: Group I will receive 1.5 ml of 0.5% hyperbaric bupivacaine (7.5 mg). Group II will receive 1.2 mL of 0.5% hyperbaric bupivacaine (6 mg) along with 0.3 mL (3 μg )of dexmedetomidine (total 1.5 mL).

Timeline

Start
2021-07-20
Primary completion
2022-02-18
Completion
2022-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 6 mg Intrathecal
Subject Bupivacaine Other / unclassified 7.5 mg Intrathecal
Subject Dexmedetomidine Other / unclassified 3 ug Intrathecal

Indications

No indication recorded.